MAP2K1 and acute lymphoblastic leukemia: These results are in line with published data on RAS mutant paediatric B-ALL samples (not MLL rearranged) that were treated with two different MAP2K1/MAPK1 inhibitors (i.e. PD98059 and U0126) showing higher cytotoxicity in the mutant samples and no effects in the RASwt specimens50.